Company intelligence / Profile preview

Libertas Bio

Ownership: Private
Development stage: Phase 3

Overview

Libertas Bio’s pipeline includes global rights to gusacitinib, an oral dual JAK/SYK inhibitor that is Phase 3-ready for chronic hand eczema and potentially other dermatological indications. The company also develops ASN008, a topical sodium channel blocker currently in a randomized double-blind Phase 2 trial for pruritus associated with atopic dermatitis. No published pivotal data yet; both programs are actively enrolling or preparing for late-stage trials as of mid/late 2024

Therapeutic areas: Dermatology
Modalities: Small molecules (e.g., gusacitinib, a dual JAK/SYK inhibitor)Topical sodium channel blockers (e.g., ASN008)
Industry: Biotech

Drug pipeline

3 assets

gusacitinib

Phase 3

Indications: Chronic hand eczema

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Libertas Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libertas Bio.

Explore the full profile